Lead Sponsor

Masonic Cancer Center, University of Minnesota

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Age \> 18 years
•Lymphoma or multiple myeloma
•Planned co-enrollment on current (at the time of this study version) or future (opening subsequent to this study) standard of care autologous stem cell transplant protocol.
•\* Must meet all eligibility requirements of the co-enrolled parent study
•Sexually active females of childbearing potential and males with partners of child-bearing potential must agree to use adequate birth control until at least day 100 post-HCT
•Voluntary written consent signed before performance of any study-related procedure not part of normal medical care

•CMV immunoglobulin, valganciclovir, ganciclovir, foscarnet, or other anti-CMV therapy within 3 months before the first vaccine is planned. Acyclovir and valacyclovir are allowed.
•Pregnant or breast feeding. The FDA has not classified this agent into a specified pregnancy category. Females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy
•Planned immunotherapy post-HCT. Proteasome inhibitors and/or immunomodulators, such as but not limited to Lenalidomide or Pomalidomide, used for myeloma maintenance are allowed.

Related studies

NCT06395103 · B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, and more

NCT07053436 · High Risk Newly Diagnosed Multiple Myeloma

NCT06615479 · Relapsed or Refractory Multiple Myeloma (RRMM)

NCT04728893 · Hematologic Malignancies, Waldenstroms Macroglobulinaemia, and more

NCT05100862 · Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma

CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig